Syncona
London-listed investment company focused on life-sciences businesses.
Syncona gives shareholders exposure to life-sciences companies, with an investment manager that supports their development towards clinical milestones and potential exits.
Last refreshed: 22 October 2026 · Appears in 1 active topic
Timeline for Syncona
Committed £10.1m to the round
UK Startups and Innovation: Oxford's OMass raises $310m on foreign leadsBackground
[Syncona](https://www.synconaltd.com/investors/) is a London-listed investment company focused on life sciences. Its investment manager creates, finances and manages a portfolio of businesses developing medical treatments. That portfolio spans companies working before clinical trials, companies testing treatments in patients and businesses with commercial products. Investors hold shares in Syncona rather than buying each portfolio company separately.
Its investment approach centres on progress that can change the value of a portfolio company, including clinical development and transactions that return capital. Acquisitions and other exits can turn those holdings into cash. Syncona's own shares trade under the ticker SYNC, while its underlying investments remain distinct businesses with their own development programmes.
What is Syncona?
What was Syncona's role in OMass's Series C?
What drug development will the OMass round support?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 22 October 2026. Editorial standards.